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reduced cXcr5 Promoter activity in 
B-cell lymphoblastic cell lines
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Chemokine receptor CXCR5 is highly expressed in B-cells and under normal conditions 
is involved in their migration to specific areas of secondary lymphoid organs. B-cells 
are known to play an important role in various autoimmune diseases including multiple 
sclerosis (MS) where areas of demyelinating lesions attract B-cells by overexpressing 
CXCL13, the CXCR5 ligand. In this study, we aimed to determine the functional signifi-
cance of single-nucleotide polymorphism rs630923 (A/C), which is located in cxcr5 gene 
promoter, and its common allele is associated with increased risk of MS. Using bioin-
formatics and pull-down assay in B-lymphoblastic cell lines, we showed that protective 
minor rs630923 “A” allele created functional binding site for MEF2C transcription factor. 
Elevated MEF2C expression in B-cells correlated with reduced activity of cxcr5 promoter 
containing rs630923 “A” allele. This effect that was fully neutralized by MEF2C-directed 
siRNA may mechanistically explain the protective role of the rs630923 minor allele in MS. 
Using site-directed mutagenesis of the cxcr5 gene promoter, we were unable to find any 
experimental evidence for the previously proposed role of NFκB transcription factors in 
rs630923-mediated CXCR5 promoter regulation. Thus, our results identify MEF2C as a 
possible mediator of protective function of the rs630923 “A” allele in MS.
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inTrODUcTiOn
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease, which affects human 
central nervous system (CNS) causing demyelination and axon loss (1). Initiation and progression of 
MS are associated with increased migration of autoreactive lymphocytes across blood-brain barrier 
(2). For a long time, T-lymphocytes have been considered as main mediators of inflammation and 
autoimmune response against CNS myelin antigens (3). This assumption was prompted by a number 
of observations such as discovery of activated T lymphocytes in MS plaques or stimulation of experi-
mental autoimmune encephalomyelitis (EAE), a mouse model of MS, by myelin-reactive T-cells. 
Although increased concentrations of antibodies and activated complement products are typical 
for MS lesions, the role of B-cells in MS propagation remained unclear until recently (4). Modern 
TaBle 1 | Oligonucleotides used in the work.
Oligonucleotide name sequence
Primers for real-time Pcr
β-actin fw 5′-TGCGTGACATTAAGGAGAAG
β-actin rev 5′-GTCAGGCAGCTCGTAGCTCT
CXCR5 fw 5′-GCTAACGCTGGAAATGGA
CXCR5 rev 5′-GCAGGGCAGAGATGATTT
Mef2c fw 5′-TGGCAACAGCAACACCTACA
Mef2c rev 5′-ATCTCGAAGGGGTGGTGGTA
Primers for amplification of cXcr5 promoter, point mutagenesis and 
amplification of fragments for pull-down assay
Prom fw GGTAAGCTTCTCGGCCTTCCAAAGTTGATT
Prom rev TAACCATGGAGAATTCCAGACAGGGCCTC
SNPreplace fw GTGAGGGCAGCCTTTAAAATAGTCATAGGC
SNPreplace rev ACTGGGGCCTATGACTATTTTAAAGGCTGC
Mef2cMut fw GCAGCCTTTAAAATAGTCATAG
Mef2cMut rev CTATGACTATTTTAAAGGCTGC
Pull-down fw TGACTTTGCGTGGTGGTTTC
Pull-down rev CACAGCATCAGTGCTAGTCAA
Pull-down control fw TGATCTCGAACTCCTGACCT
Pull-down control rev GTGCTGTGATTACAGGTGTG
Primers for site-directed mutagenesis of nFkB sites
mut1 fw GACTTAGCGGTTTCTGCAGTCAAGGGACT
mut1 rev TTGACTGCAGAAACCGCTAAGTCCTGGCA
mut2 fw TGATCAGCAGTTGAGCTCATCAACCTGCT
mut2 rev GAGCTCAACTGCTGATCAACAGAGAACAG
mut3 fw CTGTGGGCGATTTGAGCTCTTTCTTCAAA
mut3 rev AGAAAGAGCTCAAATCGCCCACAGCATCA
sirnas for Mef2c knockdown
1-sense CAACAUAUGGUACCGAGUAUU
1-antisense UACUCGGUACCAUAUGUUGUU
2-sense GAAUAACCGUAAACCAGAUUU
2-antisense AUCUGGUUUACGGUUAUUCAU
Scrambled-sense GACGUAACGCUUAGUAACAUU
Scrambled-antisense UGUUACUAAGCGUUACGUCUU
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concept of MS recognizes fundamental contribution of B-cells 
in its development. Cortical axon damage and demyelination in 
secondary MS patients are associated with formation of B-cell 
follicle-like structures in the cerebral meninges (5). The presence 
of B-lymphocytes and plasmablasts in cerebrospinal fluid and of 
plasma cells in brain tissues correlates with production of anti-
myelin autoantibodies that induce acute inflammatory response 
(6, 7). B-cells in CNS can also function as antigen-presenting 
cells and provide costimulatory signals to autoreactive T-cells 
(8). Different populations of B-lymphocytes infiltrating CNS are 
able to produce proinflammatory and regulatory cytokines such 
as IL-6, LTα, TGF-β, and IL-10 (9). These B-cells also express 
CCL22 and CCLl7 chemokines that are known to attract Th2 type 
T cells that further stimulate B-cell differentiation and antibody 
production (10).
A significant role of genetic predisposition in MS pathogenesis 
is well established, with MS risk alleles identified for a range of 
immunologically relevant loci including HLA, IL7R, IL2RA, and 
CD40 (11). Recent genome-wide association studies (GWAS) 
produced dozens of additional loci associated with MS (12, 13). 
The majority of single-nucleotide polymorphisms (SNPs) associ-
ated with MS are located outside the protein coding regions, and 
many of these SNPs reside in promoter, enhancer, or non-coding 
transcribed regions of genes that are active in B-cells (14). These 
observations corroborate with the role of B-cells in MS progres-
sion and suggest that some of the MS-associated alleles may 
directly participate in MS-related gene regulation.
Single-nucleotide polymorphism rs630923 (A/C) is located in 
the area of chemokine receptor CXCR5 gene promoter and its 
common “C” allele was shown to be associated with increased 
risk of MS (15). Under physiological conditions, chemokine 
receptor CXCR5 is highly expressed by mature B-cells and is 
responsible for B-cell homing to secondary lymphoid organs 
(11). Chemokine CXCL13, the ligand of CXCR5, is overexpressed 
in areas of actively demyelinating lesions, and almost all B-cells 
infiltrates in the CNS demonstrate high CXCR5 expression 
(12, 16), suggesting that CXCR5–CXCL13 axis is the main driver 
of B-cell recruitment to areas of MS lesions. Here, we sought to 
determine whether the minor “A” allele, associated with MS, affects 
the regulation of CXCR5 expression in B-cells. Understanding 
the role that this minor allele plays in CXCR5 regulation in B 
cells might help to explain the importance of this SNP in MS. In 
this paper, we demonstrate that activity of the CXCR5 promoter 
containing the “A” allele appears to be controlled, at least in part, 
by the MEF2C transcription factor.
MaTerials anD MeThODs
cell lines
Raji lymphoblastic cell line was kindly provided by Dr. S. E. 
Dmitriev (Belozersky Institute of Physico-Chemical Biology, 
Lomonosov Moscow State University). Daudi lymphoblastic 
cell line was obtained from Official Collection of Somatic Cell 
lines of D.I. Ivanovsky Institute of Virology of The Ministry of 
Health and Social Development of The Russian Federation. 
MCF-7 breast cancer cell line was kindly provided by Dr. E. 
Zabarovsky, Karolinska Institute (Stockholm, Sweden). MCF-7-
2si cell line with suppressed p53 was described previously (17). 
Raji and Daudi cells were cultured in RPMI 1640 medium (Life 
Technologies, Carlsbad, CA, USA) supplemented with 10% 
fetal bovine serum. MCF-7 cells were cultured in DMEM (Life 
Technologies, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum and 0.01% human insulin. For activation, 100 ng/
ml lipopolysaccharide (LPS), 5 ng/ml PMA, and 20 ng/ml iono-
mycin were added to cell culture for 24 h.
ethical approval
Scientific Council of the Engelhardt Institute of Molecular Biology 
declared no ethical approval requirements for experiments per-
formed in this study, because only commercially available cell 
lines were used.
Pull-Down assay
We used PCR to amplify a 155-bp fragment of the CXCR5 
promoter (−112/ +  43) containing rs630923. Using two-step 
PCR, we generated the variants of this fragment containing “A” 
allele of rs630923 and point mutation of MEF2C-binding site. 
An additional specificity control represented a DNA fragment 
from an upstream genome location, which did not contain 
any MEF2C-binding sites (Table  1). All PCR products were 
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verified by sequencing; sequences of all PCR primers and other 
synthetic oligonucleotides are represented in Table 1. Nuclear 
extracts from Raji and Daudi cells were isolated according to the 
published protocol (18). Nuclear extracts were incubated with 
DNA fragments and anti-MEF2C antibodies (ab79436, Abcam, 
Cambridge, UK) and precipitated with pre-blocked protein A 
sepharose beads. We quantified target DNA by real-time PCR 
after protein–DNA complexes elution and DNA purification. 
Background concentrations of the target DNA obtained for 
control reactions without lysate and without antibodies were 
subtracted from the data, which was subsequently normalized 
to the amplicon with mutant MEF2C-binding site. Rabbit IgG 
antibodies of irrelevant specificity representing an isotype 
control to the MEF2C antibody produced similar results for 
all DNA fragments regardless of the presence of the MEF2C-
binding site.
rna isolation, reverse Transcription,  
and real-Time Quantitative rT-Pcr
Total RNA was extracted from cells using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s protocol. cDNA was generated using M-MULV reverse 
transcriptase and oligo-dT primer from First strand cDNA syn-
thesis kit (Thermo Scientific, Waltham, MA, USA). Quantitative 
RT-PCR was performed using Applied Biosystems 7500 real-
time PCR amplifier, Real-time PCR reaction mix containing 
Rox and SYBR Green (Evrogen, Moscow, Russia) and specific 
primers designed to amplify intron-spanning fragments of 
human ACTB, CXCR5, and MEF2C genes (Table 1). The PCR 
program included preheating stage at 95°C for 10 min and 40 
cycles of amplification at 95°C for 15 s, 62°C for 20 s, and 72°C 
for 20 s. Melting curve analysis was used to assess the specificity 
of amplification. ACTB mRNA coding for human β-actin was 
used for normalization.
MeF2c Knockdown Using sirna
Commercially synthesized single-stranded RNA (Syntol, Moscow, 
Russia) were annealed by mixing sense and antisense RNA and 
slow cooling down from 90°C to room temperature in annealing 
buffer (5×: 50 mM Tris, 100 mM NaCl, pH 8.0). Raji cells were 
electroporated with siRNA duplexes (500  pmol per 5 million 
cells) 24 h prior to electroporation with luciferase constructs at 
which time 200 pmol more of the same siRNA duplex was added 
to prolong the silencing effect. We used two previously published 
(19) pairs of siRNAs targeting MEF2C (see Table 1). The second 
siRNA pair that turned out to be more efficient was used in all 
subsequent experiments.
Western Blot analysis
Total cell lysates were prepared using 5× Laemmli buffer. 
Protein samples (2 million cells per sample) were resolved on 
12% SDS-PAGE, transferred to Hybond-C Extra nitrocellulose 
membrane (Amersham Biosciences, Amersham, UK), stained 
with anti-MEF2C antibodies (ab79436, Abcam, Cambridge, 
UK) at 1:2000 dilution and with HRP-conjugated secondary 
anti-rabbit antibody at 1:30,000 dilution. The bands were 
visualized with ECL using SuperSignal West Dura Extended 
Duration Substrate (Thermo Scientific, Waltham, MA, USA). 
Ponceau staining served as a loading control. Gel images were 
analyzed using ImageJ software to determine the integral 
intensities of the ECL bands and of the lanes of Ponceau-
stained blots.
reporter constructs and site-Directed 
Mutagenesis
We amplified the (−455/ + 368) region of human cxcr5 promoter 
(17, 20) by PCR using genomic DNA from Raji cells as a template 
and specific primers containing cloning sites. CXCR5 promoter 
variants containing minor “A” variant of rs630923 or mutation 
in predicted MEF2C-binding site were generated by two-step 
PCR mutagenesis and verified by sequencing (see Table  1 for 
sequences of all oligonucleotides). All variants of CXCR5 pro-
moter were cloned into pGL3-basic luciferase reporter construct 
(Promega, Madison, WI, USA) using HindIII and NcoI restric-
tion sites.
electroporation and luciferase  
reporter assay
Cells were electroporated with 5 μg of purified plasmid DNA, 
and 0.1 μg of pRL-CMV renilla luciferase control reporter vec-
tor (Promega, Madison, WI, USA) using Neon Transfection 
System (Thermo Scientific, Waltham, MA, USA). For each 
cell line, we used protocols provided by the manufacturer: one 
30 ms 1300 V pulse for Raji, two 30 ms 1100 V pulses for MCF-
7, and two 30 ms 1300 V pulses for Daudi. Luciferase activity 
was measured in Luminometer 20/20n (TurnerBioSystems, 
Sunnyvale, CA, USA) using Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI, USA) following the manufac-
turer’s protocol. The activity of Firefly luciferase was normal-
ized to that of renilla luciferase to account for variations in 
transfection efficiency.
statistical analysis
We used Microsoft Excel and Statistical software for statistical 
analyses. Statistical significance was determined using two-tailed 
unpaired Student’s t-test, P-value <0.05 was considered signifi-
cant. Data for each sample represent the result of at least three 
independent experiments. Real-time PCR and luciferase assays 
were additionally performed in two technical replicates. Error 
bars in the graphs represent SEMs value.
resUlTs
Minor Ms allele of snP rs630923  
in cXcr5 Promoter creates  
MeF2c-Binding site
Single-nucleotide polymorphism rs630923 (A/C) is located 
in a highly conservative area of chemokine receptor CXCR5 
gene promoter [−31 with respect to the transcription start site 
(TSS)] and its common “C” allele was shown to be associated 
with increased risk of MS (12, 15). Since nucleotide variations 
FigUre 1 | Minor allele of snP rs630923 creates a MeF2c-binding site. (a) Schematic illustration of location of SNP rs630923 and MEF2C-binding site, 
associated with its “A” allele, in CXCR5 promoter. (B) Position weight matrix of MEF2C-binding site and the scheme of its point mutagenesis.
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this close to the TSS may affect the efficiency of transcriptional 
initiation, we hypothesized that rs630923 may influence CXCR5 
promoter activity directly and searched the CXCR5 promoter 
region for transcription factor binding sites (TFBS) that either 
appear or disappear depending on the rs630923 allele. We used 
PERFECTOS-APE software (21) with curated TFBS models 
from JASPAR and HOCOMOCO databases. The list of candidate 
transcription factors with best scores included MEF2C, MEF2A, 
FoxL1, DUX4, HNF4G, and TCF7L2. Of these, MEF2C stood 
out as the most relevant candidate since it is highly expressed 
in B-cells (22), participates in inflammation-induced B-cell 
proliferation (23), and targets a subset of B-cell-specific genes 
(24). MEF2C was also shown to influence migration potential of 
leukemic cells by targeting CCR2 and CCR5 chemokine receptors 
genes (25). Since B-cells facilitate the progression of MS (26), we 
predicted that the minor “A” rs630923 allele may play its protec-
tive role by creating a binding site for MEF2C that attenuates the 
transcription of CXCR5 gene encoding the critical chemotactic 
receptor on these cells.
We used pull-down assay to investigate the influence of 
rs630923 on MEF2C binding to the CXCR5 promoter. We con-
structed three variants of CXCR5 gene promoter (−112/ + 43) 
region (Figure  1A) containing either common “C” rs630923 
allele, minor “A” allele or a combination of the minor “A” allele 
with additional mutations disrupting the MEF2C consensus 
(Figure  1B). Pull-down assay was performed using nuclear 
extracts from two human lymphoblastic B cell lines, Raji and 
Daudi (both cell lines carry C/C rs630923 alleles). High levels 
of CXCR5 and MEF2C expression are typical for both cell lines, 
according to Broad-Novartis Cancer Cell Line Encyclopedia (27).
A significant amount of the DNA probe containing minor “A” 
rs630923 allele could be precipitated from the binding reaction 
with nuclear extracts from both cell lines using anti-MEF2C 
antibodies while the “C” probe did not significantly differ from 
the control probes, including the one with point mutation of the 
MEF2C site (Figure 2). These data demonstrate the presence of a 
MEF2C-binding site in the CXCR5 promoter containing minor 
rs630923 allele.
Presence of active MeF2c-Binding site is 
associated with reduced cXcr5 
Promoter activity
To study the role of rs630923 and associated MEF2C-binding site 
in modulation of CXCR5 promoter activity, we generated lucif-
erase reporter constructs containing CXCR5 promoter variants 
both rs630923 alleles with or without the MEF2C-binding site 
mutation (Figure 3A). In order to emulate BCR stimulation and 
costimulatory signals received by B cells migrating to MS lesions 
(28), we stimulated Raji and Daudi B-lymphoblastic cells using 
combination of LPS, PMA, and ionomycin. B-cell activation 
leads to increased MEF2C expression (22) but does not influence 
CXCR5 expression level (29, 30). These previously published 
observations were verified for CXCR5 by real-time RT-PCR using 
mRNA from Raji cells (Figure 3B) and for MEF2C by RT-PCR 
(Figure 3B) and by western blot (Figure 3C).
FigUre 2 | MeF2c binding to cXcr5 promoter depends on the rs630923 allele. The efficiency of MEF2C binding was estimated by pull-down assay using 
nuclear extracts from Raji and Daudi B-lymphoblastic cell lines. DNA fragments used for binding are schematically depicted on the left, with variants of the CXCR5 
promoter fragment as blue line segments and control fragment of CXCR5 locus as green line segment. Data were normalized to the amplicon with mutant 
MEF2C-binding site after subtraction of the background values (concentrations of the target DNA obtained for control reactions without lysate and without 
antibodies). The result of three independent experiments is shown. *P < 0.05.
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The presence of either rs630923 “A” allele and/or MEF2C-
binding site did not significantly influence the CXCR5 promoter 
under normal culture conditions, with the exception of the 
activity of the rs630923 “A” allele variant in Raji cells that was 
somewhat elevated in this particular set of experiments. However, 
B-cell activation led to a significant and specific decrease in 
CXCR5 promoter activity in both B-cell lines when the promoter 
contained the minor “A” rs630923 variant in the context of a 
functional MEF2C-binding site (Figure 3A). These data indicate 
that protective role of “A” rs630923 allele in MS (presumably 
associated with low CXCR5 and reduced migration of activated 
B-cells to areas of demyelinating lesions) may be explained by 
repression of CXCR5 promoter activity by MEF2C transcription 
factor.
To assess the role of MEF2C transcription factor directly, 
we evaluated the activities of various CXCR5 promoter vari-
ants in Raji cells upon siRNA-mediated suppression of MEF2C 
expression. We tested two variants of previously published 
siRNAs against MEF2C (see Materials and Methods), and one 
of them that caused up to 80% decrease in MEF2C mRNA 
level and insensitivity of MEF2C expression to cell activation 
(Figure  4A) was used in subsequent experiments. The activ-
ity of CXCR5 promoter lacking MEF2C-binding site (either 
“C” allele or “A” allele with MEF2C-binding site mutation) 
was essentially insensitive to both cell activation and MEF2C 
expression level. However, MEF2C knockdown completely 
abolished the decrease in the activity of CXCR5 promoter con-
taining the protective “A” allele that was observed in activated 
cells (Figure 4B). These data indicate that in our cell culture 
model, both MEF2C and rs630923 protective alleles play unique 
and essential roles in the reduction of CXCR5 promoter activity 
during B-cell activation.
nFkB status Does not influence the 
rs630923-Dependent cXcr5 Promoter 
activity in McF-7 Breast cancer cells
It has been suggested earlier that an NFkB binding site in the 
vicinity of rs630923 may play a role in cxcr5 promoter regula-
tion (15), whereas our own studies of CXCR5 promoter did not 
reveal any NFkB-binding sites overlapping this SNP (17). To 
directly access the role of rs630923 in NFkB-dependent CXCR5 
promoter activity we used MCF-7 breast cancer cell line and its 
derivative cell line MCF-7-2si with p53 knockdown (17). This 
cell culture model takes advantage of the functional antagonism 
between p53 and NFκB (31) that results in elevated NFκB activ-
ity in the absence of p53-mediated suppression (17). Both cell 
lines showed significant MEF2C expression (Figure  5A). This 
observation correlated with publically available expression data 
(27) and indicated that MEF2C effects on CXCR5 promoter 
FigUre 4 | reduced activity of cXcr5 promoter with minor “a” 
rs630923 variant in activated B- cells depends on MeF2c expression. 
(a) MEF2C expression in Raji cells electroporated with two different variants 
of anti-MEF2C siRNAs and control scrambled siRNA before and after B-cell 
activation. MEF2C mRNA was measured by real-time RT-PCR and 
normalized to ACTB (β-actin). The result of three independent experiments is 
shown. (B) The decrease in CXCR5 promoter activity in activated Raji cells 
associated with minor “A” rs630923 allele is completely abolished by MEF2C 
knockdown. The data shown were obtained in five independent experiments 
and normalized to renilla luciferase activity. *P < 0.05.
FigUre 3 | Minor “a” allele of rs630923 is responsible for reduced cXcr5 promoter activity in activated B-lymphoblastic cells. (a) Minor “A” allele of 
rs630923 reduces the CXCR5 promoter activity specifically in activated B-cells. The data shown were obtained in five independent experiments and normalized to 
renilla luciferase activity. *P < 0.01. (B) Activation does not influence the level of CXCR5 expression (top panel) but leads to increased MEF2C mRNA (bottom panel). 
The real-time RT PCR data shown are the result of three replicate experiments. (c) MEF2C protein is increased in activated Raji cells. A representative western blot 
is shown (top panel). The experiment was repeated three times, gel images were quantified using ImageJ software (bottom panel). *P < 0.05.
6
Mitkin et al. rs630923 Regulates CXCR5 Promoter in B-Cells
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 515
could be addressed in this system. The level of NFkB activity, as 
assessed by an NFkB-dependent reporter plasmid, was signifi-
cantly higher in MCF-7-2si cells (Figure 5B), again in agreement 
with our previous results (17). We then measured the activities of 
the CXCR5 promoter versions containing “C” and “A” alleles of 
the rs630923 SNP using previously described promoter variant 
with mutations in all NFkB-binding sites as a negative control 
(Figure 5C). Both test constructs were significantly more active 
in MCF-7-2si cells as compared to the parental MCF-7 cell line, 
but no significant difference between two allelic variants was 
observed. This result indicates that although CXCR5 promoter 
activity is modulated by NFkB, rs630923 is not involved in this 
process.
DiscUssiOn
Modern concept of MS pathogenesis implies an important role 
for B-cells in disease progression (4). B-cell migration to areas 
of demyelination depends on interaction of CXCL13 chemokine 
with CXCR5 chemokine receptor (16).
In this work we report functional characterization of the 
SNP rs630923 (A/C) located 31  bp upstream of the TSS of 
the CXCR5 gene. Using bioinformatics, we identified MEF2C 
transcription factor that is known to enhance B-cell prolifera-
tion and survival in response to BCR stimulation (22, 23) as the 
most likely candidate for molecular discriminator between the 
rs630923 alleles. Pull-down DNA binding assay with nuclear 
extracts from activated B-cells confirmed the prediction and 
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demonstrated MEF2C binding to the minor “A” but not to the 
common “C” rs630923 variant (Figure  2). CXCR5 promoter 
containing the “A” rs630923 variant demonstrated reduced 
ability to drive reporter gene transcription in activated B-cells 
(Figure  3); importantly, the effect was MEF2C-dependent 
(Figure  4). MEF2C has been described as an activator as it 
induces expression of a number of chemokines and their recep-
tors (24), and MEF2C loss is associated with poor homing of 
leukemic cells (25). However, in this system, MEF2C appears 
to act as a repressor of CXCR5 gene transcription in activated 
B-cells. B-cell activation has been implicated in reduced 
CXCL13-directed B-cell migration (32). Proposed mecha-
nism of this process focused on the downstream stages of the 
CXCL13/CXCR5-signaling cascade, taking into account known 
CXCR5 insensibility to B-cell activation (29). Our data indicate 
that in an appropriate genomic context, direct regulation of the 
CXCR5 gene may be involved as well.
Another question regarding CXCR5 expression in MS was 
previously proposed NFkB involvement in rs630923-mediated 
CXCR5 promoter regulation (15). Our previous experiments 
on CXCR5 promoter regulation in an NFkB-dependent system 
based on breast cancer cell lines (17) did not reveal any functional 
NFkB sites in the area of interest. We now directly tested the 
activities of CXCR5 promoter variants with different rs630923 
alleles in the same system and did not find any evidence of 
rs630923 involvement in NF-B-dependent CXCR5 gene regula-
tion (Figure 5).
In conclusion, our data suggest that protective role of the minor 
variant of rs630923 SNP in MS may result from intricate interplay 
between B-cell activation and migration mechanisms. In the 
homozygous carriers of the protective allele, BCR activation that 
is typical for MS would be counteracted by MEF2C-dependent 
downregulation of CXCR5 gene expression. That would result in 
a lower rate of CXCL13-directed B-cell migration to secondary 
lymphoid organs, reduced CNS infiltration and reduced rate of 
meningeal B-cell follicles formation (33), providing a possible 
mechanistic explanation for the low risk of MS progression asso-
ciated with the rs630923 minor allele. Whether this mechanism 
actually affects B-cell migration in MS patients should be verified 
in future studies.
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FigUre 5 | The effect of rs630923 snP on cXcr5 promoter activity in McF-7 breast cancer cells is not sensitive to nFkB status. (a) The level of 
MEF2C mRNA in MCF-7 breast cancer cells is only two times lower than in Raji cells and is not significantly sensitive to p53 knockdown. (B) NFkB activity is 
significantly higher in MCF-7 cells with p53 knockdown. (c) CXCR5 promoter activity in MCF-7 cells is sensitive to NFkB status but not to the rs630923 SNP.  
The data shown were obtained in five independent experiments and normalized to renilla luciferase activity. *P < 0.05.
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